Pharma: Page 48
-
Permission granted by Bristol-Myers Squibb
Bristol Myers melanoma drug approved by FDA in immunotherapy advance
Opdualag is first approved drug that works by targeting a protein called LAG-3 and the third type of "checkpoint inhibitor" the agency has cleared for cancer.
By Ned Pagliarulo • March 21, 2022 -
Permission granted by Emergent CDMO
Sponsored by Emergent CDMOFour key considerations to help prepare for the next public health threat
As Omicron cases continue to decline and hopes for a return to normalcy rise once again, it's tempting to let your guard down. Emergent team members reflect on lessons learned through COVID-19 and share four considerations to help prepare for the next public health threat.
March 21, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Christopher Furlong via Getty Images
AstraZeneca pays $775M to settle patent dispute over Alexion drug
The pharma reached an accord with Roche subsidiary Chugai over Ultomiris, a drug AstraZeneca acquired when it bought Alexion for nearly $40 billion.
By Kristin Jensen • March 17, 2022 -
Deep Dive // Patent thickets
Two decades and $200 billion: AbbVie’s Humira monopoly nears its end
The first biosimilar copy of Humira is set to arrive in the U.S. next week, testing both AbbVie and the market potential for knockoff biologic drugs.
By Jonathan Gardner • Updated Jan. 27, 2023 -
Courtesy of Eli Lilly
With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug
The positive results are the latest evidence supporting a broader role for so-called SGLT2 inhibitors, which started out as diabetes medicines but have since shown promise in a range of metabolic diseases.
By Jonathan Gardner • March 16, 2022 -
Courtesy of Sanofi
Sanofi lures Blackstone backing in unusual deal for multiple myeloma drug
Rather than fund development of a more convenient version of its blood cancer drug Sarclisa on its own, Sanofi has instead turned to Blackstone, which has fast become one of the sector's more active investors.
By Kristin Jensen • March 15, 2022 -
Erik S. Lesser via Getty Images
Merck bid to combine two top drugs for prostate cancer falls short
The pharma ended a large study of Keytruda and Lynparza early after disappointing results, a setback for a combination that research has suggested could treat a range of cancers.
By Ben Fidler • March 15, 2022 -
Retrieved from iStock.
Sponsored by VeradigmImplementing value-based care to drive success for life sciences companies
Value-focused solutions can help life sciences groups make the switch to value-based contracting.
March 14, 2022 -
AbbVie holds off another Humira challenger with Alvotech deal
A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.
By Ned Pagliarulo • March 9, 2022 -
Permission granted by Bristol-Myers Squibb
In first, Bristol Myers wins FDA OK for Opdivo use before surgery in lung cancer
Opdivo's approval is another step in drugmaker efforts to establish immunotherapy drugs earlier in cancer treatment.
By Ben Fidler • March 7, 2022 -
Mateusz Bartkowiak (QIAGEN)
Sponsored by QIAGENA better way to explore TCGA data
See how we fixed the metadata problem in TCGA and get the data dictionary.
March 7, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Roche, nearing major trial readouts, starts new Alzheimer's drug study
As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.
By Jonathan Gardner • March 3, 2022 -
Getty Images
Sponsored by Aytu BioPharmaPharmaceutical OTC brands are being outcompeted by private-label OTC brands in retail and e-commerce marketplaces
Self-care and the resulting increased use of over-the-counter (OTC) medications is a growing global trend.
Feb. 28, 2022 -
Getty Images
Lilly, Boehringer diabetes pill wins expanded use in heart failure
The FDA OK greatly broadens the number of patients eligible for Jardiance, which first won approval in 2014 as a treatment for low blood sugar in people with diabetes.
By Jonathan Gardner • Feb. 25, 2022 -
Courtesy of Eli Lilly
Lilly puts $700M into genetic medicine institute
Building on Lilly's acquisition of Prevail Therapeutics, the Boston-based facility will use RNA- and DNA-based technologies to develop new drugs, while also supporting biotech startups in the area.
By Jacob Bell • Feb. 22, 2022 -
Warren Little via Getty Images
Citing safety signal, GSK pauses some trials of new RSV vaccine
As RSV vaccine development heats up, the drugmaker said it will delay work on its shot for pregnant women, although separate studies in older adults remain on track.
By Jonathan Gardner • Feb. 18, 2022 -
Jacob Bell/BioPharma Dive
Merck promotes 3 executives to lead human health business
The appointments come after Frank Clyburn left to run IFF and are part of broader executive turnover at Merck.
By Kristin Jensen • Feb. 16, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly's new COVID-19 antibody becomes US' latest tool to battle omicron
The speedy clearance of Lilly’s bebtelovimab comes after the U.S. stopped distributing two of the company's earlier antibodies because they couldn't effectively neutralize the variant.
By Jonathan Gardner • Updated Feb. 11, 2022 -
Getty Images
Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback
Safety concerns, including the recent death of a patient in an early study, led the FDA to place a hold on the therapy and Pfizer to redesign its Phase 3 trial.
By Ned Pagliarulo • Feb. 10, 2022 -
Amgen expects rising sales through 2030, but Wall Street still has doubts
Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras.
By Kristin Jensen • Feb. 9, 2022 -
Lisa Maree Williams via Getty Images
Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill
The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5%.
By Ned Pagliarulo • Feb. 8, 2022 -
Courtesy of Sanofi
Sanofi's Bioverativ deal begins to pay dividends with first new drug approval
The FDA's clearance of Enjaymo for cold agglutinin disease means Sanofi has a new marketed product to show for its 2018 buyout of Biogen's former spinoff.
By Jonathan Gardner • Feb. 7, 2022 -
Courtesy of Eli Lilly
Lilly slows FDA submission of Alzheimer's drug after Medicare decision
Executives for the pharma downplayed the impact of an accelerated approval for donanemab, pointing to Medicare's plans to restrict coverage of Alzheimer's drugs like it to only patients in clinical trials.
By Jonathan Gardner • Feb. 3, 2022 -
Courtesy of Pfizer
Pfizer, BioNTech begin process of asking FDA for COVID-19 vaccine clearance in young kids
The companies said the FDA, in an unusual step, requested they submit the clinical trial data they currently have while testing of a third dose in children under 5 years of age continues.
By Kristin Jensen • Feb. 2, 2022 -
Dan Kitwood via Getty Images
Pfizer lures research chief from Roche, prompting high-level reshuffle
William Pao led discovery and early development at the Swiss drugmaker, and will now head Pfizer's global efforts to launch new products.
By Jonathan Gardner • Feb. 1, 2022
Previous
